Dombrovski Alexandre Y, Cyranowski Jill M, Mulsant Benoit H, Houck Patricia R, Buysse Daniel J, Andreescu Carmen, Thase Michael E, Mallinger Alan G, Frank Ellen
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Depress Anxiety. 2008;25(12):1060-6. doi: 10.1002/da.20467.
Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression.
We analyzed data on 131 women aged 20-60 from a 2-year randomized trial of weekly versus twice-monthly versus monthly IPT-M. Participants achieved remission with IPT alone (n=99) or IPT plus sequential antidepressant medication (n=32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models.
Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence. Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia (18%).
Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication.
即使是低水平的残留症状也会增加重度抑郁症复发和早期复发的风险。目前尚不清楚持续的心理治疗是否能降低这种风险。因此,我们研究了包括情绪、失眠和焦虑症状在内的持续性症状对接受复发性抑郁症维持性人际心理治疗(IPT-M)的女性复发时间的影响。
我们分析了131名年龄在20至60岁之间女性的数据,这些数据来自一项为期2年的随机试验,该试验比较了每周一次、每两周一次和每月一次的IPT-M。参与者单独通过IPT实现缓解(n = 99)或通过IPT加序贯抗抑郁药物实现缓解(n = 32)。在开始维持治疗前逐渐减少药物剂量。使用汉密尔顿抑郁量表(HRSD;总分及各子量表)评估残留症状;还使用匹兹堡睡眠质量指数(PSQI)对76名女性的失眠情况进行了评估。数据分析采用Cox比例风险回归模型。
残留症状的总体负担(HRSD总分)以及HRSD情绪和焦虑子量表得分均不能预测正在进行IPT-M治疗期间的复发情况。相比之下,通过HRSD-17失眠子量表和PSQI测量的持续性失眠可预测复发。与需要序贯治疗但无失眠的女性(13%)、仅通过IPT康复但有持续性失眠的女性(21%)或无失眠的女性(18%)相比,需要序贯药物治疗的持续性失眠女性复发率最高(65%)。
复发性重度抑郁症发作康复后出现的持续性失眠与复发风险增加有关,尽管进行了维持性心理治疗,尤其是对于那些停用抗抑郁药物的患者。